Science Corp. is gearing up to implant its first brain sensor in a human patient, marking a major milestone for Max Hodak's neurotechnology venture. The device aims to treat neurological conditions through gentle electrical stimulation, potentially offering new hope for patients with brain and spinal cord damage. If successful, the trial could position Science Corp. as a serious competitor in the rapidly evolving brain-computer interface race alongside established players.
Science Corp. is taking its boldest step yet into the human brain. The neurotechnology startup founded by Max Hodak, former president of Neuralink, is preparing to implant its first brain sensor in a human patient, a watershed moment that could redefine how we treat neurological damage.
The timing couldn't be more charged. Brain-computer interfaces have exploded from sci-fi speculation to clinical reality over the past two years, with multiple companies racing to prove their technology works in actual humans. Science Corp.'s entry into human trials puts Hodak's vision directly up against the industry he helped create.
What sets this device apart is its therapeutic approach. Rather than focusing purely on reading brain signals or restoring motor function, Science Corp.'s sensor delivers targeted electrical stimulation to damaged neural tissue. The goal is to kickstart the body's natural healing processes in brain and spinal cord cells that have been injured through trauma, disease, or degeneration.
"The device could help address multiple neurological conditions if it proves successful," according to details shared with TechCrunch. The initial focus centers on delivering gentle electrical pulses to damaged tissue, a technique that builds on decades of neurostimulation research but packages it in Science Corp.'s proprietary sensor technology.
Hodak's departure from Neuralink in 2021 set the stage for this moment. While his former company grabbed headlines with high-profile demonstrations and Elon Musk's promotional firepower, Hodak quietly assembled a team and raised capital to pursue a different vision. Science Corp. has largely operated under the radar compared to its flashier competitors, making this human trial announcement all the more significant.
The broader BCI landscape has matured dramatically since Science Corp.'s founding. Neuralink successfully implanted its device in human patients earlier this year, while competitors like Synchron and Paradromics have advanced their own clinical programs. The field has shifted from proving the concept works to demonstrating whose approach works best, and for which conditions.
Science Corp.'s therapeutic angle could carve out distinct territory in this crowded market. Most BCI companies focus on restoring function for paralyzed patients or creating new interfaces between brains and computers. A device specifically designed to promote neural healing addresses a different medical need entirely, one that could apply to stroke victims, spinal cord injury patients, and people suffering from neurodegenerative diseases.
The technical challenges are formidable. Delivering precise electrical stimulation to damaged tissue requires exquisite control over current, timing, and location. The sensor must remain stable and biocompatible inside the brain for extended periods while accurately targeting the right cells. And proving that stimulation actually promotes healing, rather than just producing temporary effects, will require rigorous clinical data.
Regulatory pathways for these devices remain complex. The FDA has been cautiously supportive of BCI development but demands extensive safety and efficacy data before granting broader approvals. Science Corp. will need to demonstrate not just that its device is safe to implant, but that the therapeutic benefits justify the surgical risks.
The neurotechnology investment landscape has heated up considerably as companies move from animal studies to human trials. Venture capital poured more than $600 million into BCI startups last year alone, betting that one or more of these technologies will crack open a massive medical market. Science Corp. has raised significant funding to reach this milestone, though the company hasn't disclosed recent valuation figures.
What happens next depends entirely on how this first human implant performs. The patient will be monitored intensively for safety signals, device functionality, and any early signs that the electrical stimulation is having its intended effect. Even preliminary positive results could accelerate Science Corp.'s timeline and attract additional investment, while setbacks could force the team back to the drawing board.
The broader implications extend beyond Science Corp.'s immediate fortunes. Every successful human trial in the BCI space validates the underlying technology and builds the case for wider adoption. Conversely, high-profile failures could spook regulators and investors alike. The stakes are high not just for Hodak's company, but for the entire neurotechnology sector watching closely as these first-generation devices move into human testing.
Science Corp.'s first human brain sensor implant represents more than just another clinical milestone in the BCI race. It's a test of whether neurotechnology can move beyond assistive devices into genuine therapeutic territory, using electrical stimulation to heal rather than just bypass damaged neural circuits. For Max Hodak, it's a chance to prove his post-Neuralink vision can deliver real medical breakthroughs. For the broader neurotechnology field, it's another data point in the ongoing experiment of whether we can safely and effectively interface with the human brain to treat conditions that have long resisted conventional medicine. The results from this first patient could shape the trajectory of neural therapy for years to come.
